DK0920422T3 - Krystallinsk form af 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamid - Google Patents

Krystallinsk form af 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamid

Info

Publication number
DK0920422T3
DK0920422T3 DK97938656T DK97938656T DK0920422T3 DK 0920422 T3 DK0920422 T3 DK 0920422T3 DK 97938656 T DK97938656 T DK 97938656T DK 97938656 T DK97938656 T DK 97938656T DK 0920422 T3 DK0920422 T3 DK 0920422T3
Authority
DK
Denmark
Prior art keywords
phenylisoxazol
benzenesulfonamide
methyl
crystalline form
crystalline
Prior art date
Application number
DK97938656T
Other languages
Danish (da)
English (en)
Inventor
J Talley John
R Medich John
T Mclaughlin Kathleen
T Gaud Henry
E Yonan Edward
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of DK0920422T3 publication Critical patent/DK0920422T3/da

Links

Classifications

    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/40—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs
    • H01L23/4006—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs with bolts or screws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/42—Fillings or auxiliary members in containers or encapsulations selected or arranged to facilitate heating or cooling
    • H01L23/427—Cooling by change of state, e.g. use of heat pipes
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/0001—Technical content checked by a classifier
    • H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Power Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Computer Hardware Design (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Liquid Crystal Substances (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DK97938656T 1996-08-14 1997-08-12 Krystallinsk form af 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamid DK0920422T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2437896P 1996-08-14 1996-08-14
PCT/US1997/015126 WO1998006708A1 (en) 1996-08-14 1997-08-12 Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide

Publications (1)

Publication Number Publication Date
DK0920422T3 true DK0920422T3 (da) 2003-03-17

Family

ID=21820280

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97938656T DK0920422T3 (da) 1996-08-14 1997-08-12 Krystallinsk form af 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamid

Country Status (39)

Country Link
US (2) US6441014B2 (lt)
EP (2) EP1283203A1 (lt)
JP (2) JP3631763B2 (lt)
KR (1) KR100383148B1 (lt)
CN (1) CN1205193C (lt)
AP (1) AP1055A (lt)
AR (1) AR009244A1 (lt)
AT (1) ATE228117T1 (lt)
AU (1) AU722072B2 (lt)
BG (1) BG64259B1 (lt)
BR (1) BR9711151A (lt)
CA (1) CA2264104A1 (lt)
CZ (1) CZ297679B6 (lt)
DE (1) DE69717281T2 (lt)
DK (1) DK0920422T3 (lt)
EA (2) EA003754B1 (lt)
EE (1) EE04237B1 (lt)
ES (1) ES2188971T3 (lt)
GE (1) GEP20022636B (lt)
HK (1) HK1023125A1 (lt)
HU (1) HUP0400923A3 (lt)
IL (2) IL128255A (lt)
IS (1) IS1989B (lt)
LT (1) LT4551B (lt)
LV (1) LV12274B (lt)
NO (1) NO312461B1 (lt)
NZ (1) NZ334132A (lt)
OA (1) OA11298A (lt)
PL (1) PL191313B1 (lt)
PT (1) PT920422E (lt)
RO (1) RO120771B1 (lt)
RS (1) RS49671B (lt)
SI (1) SI9720059B (lt)
SK (1) SK283558B6 (lt)
TR (1) TR199900298T2 (lt)
TW (1) TW527350B (lt)
UA (1) UA52684C2 (lt)
WO (1) WO1998006708A1 (lt)
ZA (1) ZA977314B (lt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9711151A (pt) * 1996-08-14 1999-08-17 Searle & Co Forma cristalina de 4-¬5-metil-3-fenilsoxazol-4-il¾benzenossulfonamida
NZ333399A (en) * 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
GB9810920D0 (en) * 1998-05-21 1998-07-22 Merck Sharp & Dohme Therapeutic use
WO2000008001A1 (en) * 1998-08-07 2000-02-17 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
AU1398899A (en) * 1998-11-12 2000-06-05 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
NZ513924A (en) * 1999-03-01 2001-09-28 Ortho Mcneil Pharm Inc Composition comprising a tramadol material and a selective cox-2 inhibitor drug
AU782759B2 (en) 1999-08-20 2005-08-25 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
EP1212051A4 (en) * 1999-08-27 2004-03-31 Merck & Co Inc METHOD FOR TREATING OR PREVENTING CHEMICAL PROSTATITIS OR CHRONIC POOL PAIN
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
EP3168218B1 (en) * 2001-08-15 2018-11-14 Pharmacia & Upjohn Company LLC A crystal comprising an l-malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide for use as a medicament
US20070072921A1 (en) * 2002-07-26 2007-03-29 Talley John J Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
AU2003238668A1 (en) 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
CA2519189C (en) 2003-05-07 2012-07-17 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US20050182113A1 (en) * 2003-12-30 2005-08-18 Venkataraman Sundaram Method for preparing diaryl-substituted isoxazole compounds
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib
WO2005120499A1 (en) * 2004-06-10 2005-12-22 Chandiran Thakashinamoorthy Form a of valdecoxib suitable for pharmaceutical formulations
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
SI1612203T1 (sl) * 2004-06-28 2007-12-31 Gruenenthal Chemie Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
KR100591786B1 (ko) 2004-10-19 2006-06-26 휴먼팜 주식회사 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법
AU2006249577A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
JP2009537635A (ja) 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
CA2729056A1 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103172583A (zh) * 2013-03-07 2013-06-26 深圳市资福药业有限公司 一种制备帕瑞昔布的方法
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
CN114441666B (zh) * 2020-11-05 2024-02-27 成都百裕制药股份有限公司 一种4-(5-甲基-3-苯基-4-异恶唑)苯磺酰氯中杂质的检测方法
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
WO1996025405A1 (en) * 1995-02-13 1996-08-22 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
BR9711151A (pt) * 1996-08-14 1999-08-17 Searle & Co Forma cristalina de 4-¬5-metil-3-fenilsoxazol-4-il¾benzenossulfonamida
AU2003238668A1 (en) * 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib

Also Published As

Publication number Publication date
NZ334132A (en) 2000-06-23
EP1283203A1 (en) 2003-02-12
PT920422E (pt) 2003-03-31
DE69717281D1 (de) 2003-01-02
JP3631763B2 (ja) 2005-03-23
OA11298A (en) 2003-10-22
AR009244A1 (es) 2000-04-12
BG64259B1 (bg) 2004-07-30
AU4093697A (en) 1998-03-06
TW527350B (en) 2003-04-11
IL161224A0 (en) 2004-09-27
NO312461B1 (no) 2002-05-13
UA52684C2 (uk) 2003-01-15
HK1023125A1 (en) 2000-09-01
CZ297679B6 (cs) 2007-03-07
YU7499A (sh) 2000-03-21
SK13699A3 (en) 1999-07-12
JP2005015497A (ja) 2005-01-20
CN1205193C (zh) 2005-06-08
JP2000506542A (ja) 2000-05-30
EE04237B1 (et) 2004-02-16
TR199900298T2 (xx) 1999-05-21
US20010003752A1 (en) 2001-06-14
LT99024A (lt) 1999-07-26
EA200000891A1 (ru) 2001-02-26
IS1989B (is) 2005-02-15
PL191313B1 (pl) 2006-04-28
IS4961A (is) 1999-01-29
ATE228117T1 (de) 2002-12-15
CN1233243A (zh) 1999-10-27
SI9720059B (sl) 2011-11-30
EA001472B1 (ru) 2001-04-23
PL331607A1 (en) 1999-08-02
KR100383148B1 (ko) 2003-05-09
US20030004200A1 (en) 2003-01-02
IL128255A (en) 2004-06-20
IL128255A0 (en) 1999-11-30
EA003754B1 (ru) 2003-08-28
WO1998006708A1 (en) 1998-02-19
RS49671B (sr) 2007-11-15
CA2264104A1 (en) 1998-02-19
LV12274A (lv) 1999-05-20
LV12274B (en) 1999-09-20
LT4551B (lt) 1999-10-25
EP0920422A1 (en) 1999-06-09
RO120771B1 (ro) 2006-07-28
NO990541L (no) 1999-02-05
CZ33499A3 (cs) 1999-06-16
AP1055A (en) 2002-04-04
KR20000029994A (ko) 2000-05-25
BG103155A (en) 1999-11-30
ZA977314B (en) 1998-08-14
BR9711151A (pt) 1999-08-17
AU722072B2 (en) 2000-07-20
HUP0400923A3 (en) 2007-11-28
GEP20022636B (en) 2002-02-25
EA199900200A1 (ru) 1999-06-24
EE9900053A (et) 1999-08-16
DE69717281T2 (de) 2003-09-04
US7135489B2 (en) 2006-11-14
SI9720059A (sl) 1999-12-31
US6441014B2 (en) 2002-08-27
HUP0400923A2 (hu) 2004-08-30
ES2188971T3 (es) 2003-07-01
EP0920422B1 (en) 2002-11-20
AP9901458A0 (en) 1999-03-31
SK283558B6 (sk) 2003-09-11
NO990541D0 (no) 1999-02-05

Similar Documents

Publication Publication Date Title
DK0920422T3 (da) Krystallinsk form af 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamid
DK0975778T3 (da) Anvendelse af glyphostat-resistende majslinier
DK0991641T3 (da) Krystallinsk form af omeprazol-natriumsalt
ID24481A (id) Gastrokinetik monosiklik benzamida dari derivat-3-atau-tersubstitusi 4-(aminometil)-piperidin
DK1107980T3 (da) Krystallinske former af EtO2C-CH2-(R)Cgl-Aze-Pab-OH
DK1149090T3 (da) Ny krystallinsk form af kaliumsalt af (S)-omeprazol
NO984290D0 (no) Farmas°ytisk nyttige forbindelser
DK0873308T3 (da) O-Carbamoyl-phenylalaninol-forbindelser og deres farmaceutisk anvendelige salte
DE69942085D1 (de) Monolithischer keramischer Kondensator
DE60107074D1 (de) Kristallin form ii von cabergolin
DK1196431T3 (da) En i det væsentlige krystallinsk form af melagatran
IS5821A (is) Kristalluð form af ósanetant
IS6620A (is) Nýr fjölgervingur V af tórasemíði
DK0941081T3 (da) Ny anvendelse af creatin
DK1001962T3 (da) Fremstilling af avermectinforbindelser
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
DK1088010T3 (da) Fremstilling af polyolefiner
DK0882722T3 (da) Fremstilling af alpha-tocopherol
DK0859001T3 (da) Fremstilling af oxazolderivater
DK0747056T3 (da) Minimering af knogletab med anti-estrogenkombinationer
DK0950051T3 (da) Mikropartikulær form af en tetrahydropyridinforbindelse
NO20004583D0 (no) Krystallinsk form av paroxetine
EE200400073A (et) 4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm ja selle kasutamine
DK0980383T3 (da) Farmaceutisk acceptable salte af 3-hydroxy-østr-5(10)-en-17-on-3-sulfat aktive som østrogener
DK108697A (da) Disruption of iapp fibrils